Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14), Bloomberg Earnings reports.

Shares of Ritter Pharmaceuticals (NASDAQ RTTR) traded down 2.0833% on Tuesday, reaching $0.5875. The company’s stock had a trading volume of 57,899 shares. The company’s market capitalization is $8.59 million. Ritter Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $3.75. The stock has a 50-day moving average price of $0.58 and a 200-day moving average price of $1.53.

Several research firms have issued reports on RTTR. Chardan Capital cut their target price on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a research note on Tuesday. Zacks Investment Research downgraded Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Maxim Group reissued a “hold” rating on shares of Ritter Pharmaceuticals in a report on Wednesday, July 5th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $4.88.

ILLEGAL ACTIVITY WARNING: “Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Posts Quarterly Earnings Results, Meets Estimates” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/ritter-pharmaceuticals-inc-nasdaqrttr-posts-quarterly-earnings-results-meets-estimates.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Earnings History for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.